



SUPPLEMENTARY FIG. S2. (Continued).

C

Alb30Q2W	1.47 (0.30,6.14)	Ab30QW	1.23 (0.30,5.63)	Alb30Q2W	0.87 (0.19,4.72)	Alb50QM	0.91 (0.15,4.31)	Alb50QM	0.98 (0.26,4.31)
1.31	0.96 (0.39,4.66)	1.02 (0.20,4.05)	1.07 (0.28,3.75)	1.07 (0.29,3.60)	EX10BID				
1.21	0.90 (0.36,4.56)	0.95 (0.17,3.86)	1.01 (0.26,3.67)	0.94 (0.25,3.48)	EX2QW				
1.43	1.05 (0.41,5.46)	1.12 (0.22,4.67)	1.17 (0.29,4.40)	1.09 (0.29,4.13)	1.16 (0.69,1.72)	EX5BID			
1.14	0.85 (0.32,4.60)	0.91 (0.16,3.96)	0.94 (0.23,3.72)	0.89 (0.23,3.60)	0.95 (0.50,1.56)	0.82 (0.52,1.77)	LIR0.6QD		
0.77	0.58 (0.22,2.96)	0.62 (0.12,2.55)	0.64 (0.16,2.43)	0.60 (0.16,2.29)	0.64 (0.35,0.96)	0.55 (0.36,1.08)	UR1.2QD		
0.73	0.54 (0.21,2.74)	0.57 (0.11,2.36)	0.60 (0.15,2.19)	0.57 (0.16,2.14)	0.60 (0.38,0.84)	0.52 (0.39,0.93)	0.63 (0.29,0.91)	0.94 (0.65,1.43)	UR1.8QD
1.57	1.15 (0.30,10.23)	1.26 (0.21,8.33)	1.22 (0.21,8.23)	1.31 (0.24,7.83)	1.22 (0.37,4.53)	1.10 (0.37,5.17)	1.37 (0.32,4.39)	2.05 (0.57,5.63)	2.16 (0.61,8.48)
1.78	1.33 (0.53,6.86)	1.43 (0.25,5.80)	1.50 (0.38,5.62)	1.38 (0.88,2.55)	1.48 (0.92,2.14)	1.27 (0.74,2.29)	1.57 (0.82,2.99)	2.31 (1.29,4.43)	2.47 (1.48,4.23)
0.55	0.40 (0.12,3.10)	0.42 (0.06,2.48)	0.44 (0.08,2.42)	0.41 (0.09,2.26)	0.44 (0.15,1.42)	0.37 (0.13,1.26)	0.47 (0.15,1.57)	0.69 (0.22,2.38)	0.73 (0.24,2.37)
2.55	1.86 (0.48,18.44)	2.02 (0.20,14.84)	1.92 (0.37,14.16)	1.87 (0.37,12.56)	1.98 (0.57,8.09)	1.68 (0.47,7.94)	2.07 (0.59,9.78)	3.11 (0.88,14.36)	3.31 (0.96,14.75)
3.36	2.09 (0.38,28.64)	2.74 (0.33,17.02)	2.60 (0.28,21.95)	2.39 (0.28,25.10)	2.56 (0.45,17.64)	2.20 (0.41,16.06)	4.08 (0.46,25.18)	4.28 (0.71,31.71)	4.97 (0.78,33.92)
4.32	2.80 (0.50,28.18)	3.33 (0.39,23.72)	3.25 (0.37,22.53)	2.96 (0.37,21.25)	2.72 (0.55,16.67)	3.15 (0.58,17.51)	4.98 (0.49,15.51)	5.26 (0.89,29.30)	5.26 (0.94,29.57)
1.42	0.98 (0.22,9.22)	1.28 (0.18,7.65)	1.26 (0.17,7.24)	1.14 (0.26,4.04)	1.23 (0.27,4.62)	1.04 (0.24,3.92)	1.32 (0.27,5.01)	2.01 (0.40,7.60)	2.95 (0.45,7.58)
0.94	0.64 (0.16,5.32)	0.76 (0.12,4.35)	0.71 (0.12,3.93)	0.75 (0.21,2.56)	0.65 (0.21,3.42)	0.78 (0.33,4.69)	1.17 (0.36,4.77)	1.23 (0.10,3.01)	1.75 (0.51,1.94)
1.65	1.18 (0.46,6.43)	1.30 (0.28,5.51)	1.36 (0.34,5.25)	1.26 (0.76,2.08)	1.36 (0.75,2.37)	1.15 (0.61,2.17)	1.42 (0.70,2.85)	2.25 (1.12,4.18)	1.03 (1.24,4.01)
1.04	0.78 (0.21,7.26)	0.81 (0.10,5.88)	0.82 (0.14,6.18)	0.80 (0.14,5.45)	0.85 (0.22,3.17)	0.74 (0.23,3.51)	0.89 (0.23,4.05)	1.32 (0.38,5.97)	1.42 (0.38,5.85)
								0.66 (0.11,3.84)	0.58 (0.11,3.84)
								0.45 (0.36,10.25)	0.71 (0.12,5.12)
								0.27 (0.04,2.28)	1.13 (0.19,2.59)
								0.64 (0.12,6.57)	

SUPPLEMENTARY FIG. S2. Results of estimated odds ratio (95% confidence interval) for major gastrointestinal adverse events between different dose regimens of glucagon-like peptide-1 receptor agonists. Alb30Q2W, albiglutide 30 mg once biweekly; Alb50QW, albiglutide 30 mg once weekly; Alb50Q2W, albiglutide 50 mg once biweekly; Alb50QM, albiglutide 50 mg once monthly; EX10BID, exenatide 10 μ g twice daily; EX2QW, exenatide 2 mg once weekly; EX5BID, exenatide 5 μ g twice daily; LIR1.8QD, liraglutide 1.8 mg once daily; LIR1.2QD, liraglutide 1.2 mg once daily; LIX20BID, lixisenatide 20 μ g twice daily; LIX30BID, lixisenatide 30 μ g once daily; LIX30QD, lixisenatide 30 μ g twice daily; LY0.5/1.0, LY2189265 0.5 mg once weekly for 4 weeks, then 1.0 mg once weekly for 12 weeks; LY1.0/2.0, 1.0 mg once weekly for 4 weeks, then 2.0 mg once weekly for 12 weeks; TAS20QW, tasoglutide 20 mg once biweekly; TAS30QW, tasoglutide 30 mg once weekly.